Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Berta Hernández‐Marín
Observed names:
B. Hernandez Marin,
B. Hernandez-Marin,
B. Hernández-Marín,
Berta Hernandez-Marin,
Berta Hernández Marín,
Berta Hernández-Marín
show all 6
Institutions:
Hospital Universitario de La Princesa,
Sociedad Española de Oncología Médica
Observed institutions:
University of Alabama at Birmingham,
Complejo Hospitalario de Navarra,
Hospital Universitario de La Princesa,
Sociedad Española de Oncología Médica,
Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa,
Universidad Autónoma de Madrid
show all 6
OpenAlex ID:
A5020245346
PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer
2019
·
Ana Bocanegra
, Gonzalo Fernandez-Hinojal
, et al.
·
International Journal of Molecular Sciences
·
78
PDF
Emotional Distress in Cancer Patients During the First Wave of the COVID-19 Pandemic
2021
·
Patricia Toquero
, Carmen Blanco Fernández
, et al.
·
Frontiers in Psychology
·
30
PDF
Is Older Age an Independent Prognostic Factor of Survival in Metastatic Colorectal Cancer?
2024
·
Patricia Toquero
, Rebeca Mondéjar
, et al.
·
Oncology
·
10
PDF
Neoadjuvant Treatment in Locally Advanced Thyroid Carcinoma
2024
·
Víctor Navas Moreno
, Fernando Sebastián Valles
, et al.
·
Journal of Clinical Medicine
·
8
PDF
Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: results from the real-world Spanish Melanoma Registry (GEM-1801)
2025
·
Pablo Ayala-de Miguel
, Eva Muñoz-Couselo
, et al.
·
Clinical & Translational Oncology
·
6
Chemokine Receptors in Peripheral Blood Mononuclear Cells as Predictive Biomarkers for Immunotherapy Efficacy in Non-Small Cell Lung Cancer
2025
·
Paloma Galera
, Antía Iglesias-Beiroa
, et al.
·
Current Oncology
·
4
PDF
Pre-treatment CD4 senescent T cells accurately predicts lack of response to PD-L1/PD-1 immune checkpoint blockade in non-small cell lung cancer and correlates with risk of hyperprogression
2018
·
M. Zuazo
, H. Arasanz
, et al.
·
Annals of Oncology
·
3
Immunotherapy/biological Therapies
2013
·
J. Campian
, D. Gladstone
, et al.
·
Neuro-Oncology
·
3
PDF
Longitudinal Clinical, Physiological, and Molecular Profiling of Female Patients With Metastatic Cancer: Protocol and Feasibility of a Multicenter High-Definition Oncology Study
2026
·
Leonardo D. Garma
, Sonia Pernas
, et al.
·
JCO Precision Oncology
·
2
PDF
Venous and arterial thromboembolic events associated with osimertinib in patients with lung cancer: a study by the thrombosis and cancer group of the spanish society of medical oncology (SEOM)
2026
·
Manuel Sánchez Cánovas
, Javier López Robles
, et al.
·
Clinical & Translational Oncology
PDF
Response to Sonidegib in Advanced Basal Cell Carcinomas by Histological Subtype: A Real‐World Cohort
2025
·
Ana Jiménez‐Sánchez
, Óscar Muñoz Moreno‐Arrones
, et al.
·
International Journal of Dermatology
63P: Osimertinib for patients with EGFRm non-small cell lung cancer: Analysis of the locally advanced/metastatic cohort (OSIREAL study)
2025
·
D. Rodriguez Abreu
, M.E. Lazaro
, et al.
·
Journal of Thoracic Oncology
PDF
[Artículo traducido] ¿Es útil la proteína S100b en el seguimiento de pacientes con melanoma cutáneo no metastásico? Un estudio de cohortes en práctica clínica real
2025
·
L. Martos-Cabrera
, B. Hernández-Marín
, et al.
·
Actas Dermo-Sifiliográficas
Is S100B Protein Useful in the Follow Up of Non-Metastatic Cutaneous Melanoma Patients? A Real-World Cohort Study
2024
·
L. Martos-Cabrera
, B. Hernández-Marín
, et al.
·
Actas Dermo-Sifiliográficas
Show more works
View as search
Works count:
14
Citation count:
144
H-index:
5
I10-index:
3
Year
Topic
Type